Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2

(2016) David D. Stenehjem et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2

(2015) Anne V. Soerensen et al.   ACTA ONCOLOGICA

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

(2015) P F Ferrucci et al.   BRITISH JOURNAL OF CANCER

Kidney Cancer, Version 3.2015

(2015) Robert J. Motzer et al.   Journal of the National Comprehensive Cancer Network

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States

(2015) Christopher B. Allard et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis

(2015) K. Hu et al.   BMJ Open

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio

(2014) Arnoud J. Templeton et al.   CANCER

Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy

(2014) Boyd R. Viers et al.   EUROPEAN UROLOGY

The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer

(2013) Graeme J.K. Guthrie et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma

(2013) Michela de Martino et al.   JOURNAL OF UROLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY